Search results
Jump to navigation
Jump to search
Page title matches
- {{Short description|Substance that decreases activity of xanthine oxidase, an enzyme involved in purine metabolism}} ...nt of [[hyperuricemia]] and related medical conditions including [[gout]]. Xanthine oxidase inhibitors are being investigated for management of [[reperfusion i ...3 KB (426 words) - 20:15, 22 April 2024
- {{Short description|Substance that decreases activity of xanthine oxidase, an enzyme involved in purine metabolism}} ...nt of [[hyperuricemia]] and related medical conditions including [[gout]]. Xanthine oxidase inhibitors are being investigated for management of [[reperfusion i ...3 KB (407 words) - 19:50, 22 April 2024
- ...ase inhibitor'''）は、[[purine metabolism/ja|プリン代謝]]に関与する[[enzyme/ja|酵素]]である[[xanthine oxidase/ja|キサンチンオキシダーゼ]]の活性を[[enzyme inhibitor/ja|阻害薬]]する物質である。 [[human/ja| [[Category:Xanthine oxidase inhibitors| ]] ...4 KB (253 words) - 20:16, 22 April 2024
Page text matches
- Catalysis of the reaction: xanthine + H2O + O2 = urate + hydrogen peroxide.4 statements, 0 sitelinks - 15:18, 22 April 2024
- Catalysis of the reaction: xanthine + NAD+ + H2O = urate + NADH + H+.4 statements, 0 sitelinks - 15:24, 22 April 2024
- Substance that decreases activity of xanthine oxidase, an enzyme involved in purine metabolism3 statements, 1 sitelink - 19:21, 22 April 2024
- Catalysis of the reaction: 2-oxoglutarate (alpha-ketoglutarate) + O2 + xanthine = CO2 + succinate + urate.4 statements, 0 sitelinks - 15:26, 22 April 2024
- Catalysis of the reaction: 5-phospho-alpha-D-ribose 1-diphosphate + xanthine = (9-D-ribosylxanthine)-5'-phosphate + diphosphate.4 statements, 0 sitelinks - 10:24, 15 February 2024
- {{Short description|Substance that decreases activity of xanthine oxidase, an enzyme involved in purine metabolism}} ...nt of [[hyperuricemia]] and related medical conditions including [[gout]]. Xanthine oxidase inhibitors are being investigated for management of [[reperfusion i ...3 KB (407 words) - 19:50, 22 April 2024
- {{Short description|Substance that decreases activity of xanthine oxidase, an enzyme involved in purine metabolism}} ...nt of [[hyperuricemia]] and related medical conditions including [[gout]]. Xanthine oxidase inhibitors are being investigated for management of [[reperfusion i ...3 KB (426 words) - 20:15, 22 April 2024
- ...ase inhibitor'''）は、[[purine metabolism/ja|プリン代謝]]に関与する[[enzyme/ja|酵素]]である[[xanthine oxidase/ja|キサンチンオキシダーゼ]]の活性を[[enzyme inhibitor/ja|阻害薬]]する物質である。 [[human/ja| [[Category:Xanthine oxidase inhibitors| ]] ...4 KB (253 words) - 20:16, 22 April 2024
- The chemical reactions and pathways involving a nucleobase, a nitrogenous base that is a constituent of a nucleic acid, e.g. the purines: adenine, guanine, hypoxanthine, xanthine and the pyrimidines: cytosine, uracil, thymine.5 statements, 0 sitelinks - 08:03, 6 June 2023
- The chemical reactions and pathways resulting in the formation of the molybdopterin cofactor (Moco), essential for the catalytic activity of some enzymes, e.g. sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. The cofactor consists of a7 statements, 0 sitelinks - 20:08, 2 April 2024
- The chemical reactions and pathways involving the molybdopterin cofactor (Moco), essential for the catalytic activity of some enzymes, e.g. sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. The cofactor consists of a mononuclear molybden8 statements, 0 sitelinks - 20:06, 2 April 2024
- ...|アナフィラキシー]]などがある。[[pregnancy/ja|妊娠中]]や[[breastfeeding/ja|授乳中]]の使用は推奨されない。[[xanthine oxidase/ja|キサンチンオキシダーゼ]]を阻害し、体内での[[uric acid/ja|尿酸]]の産生を抑える。 ...inhibition/ja|非競合的阻害]]することで作用する。キサンチンオキシダーゼは、[[hypoxanthine/ja|ヒポキサンチン]]と[[xanthine/ja|キサンチン]]を相次いで尿酸に酸化するのに必要である。したがって、フェブキソスタットはキサンチンオキシダーゼを阻害し、尿酸の産生を抑える。フェブ ...11 KB (519 words) - 20:40, 22 April 2024
- ...s not recommended during [[pregnancy]] or [[breastfeeding]]. It inhibits [[xanthine oxidase]], thus reducing production of [[uric acid]] in the body. ...uric acid. Febuxostat inhibits both the oxidized and the reduced forms of xanthine oxidase by virtue of its tight binding to the molybdenum pterin site. ...9 KB (1,260 words) - 20:24, 22 April 2024
- ...s not recommended during [[pregnancy]] or [[breastfeeding]]. It inhibits [[xanthine oxidase]], thus reducing production of [[uric acid]] in the body. ...uric acid. Febuxostat inhibits both the oxidized and the reduced forms of xanthine oxidase by virtue of its tight binding to the molybdenum pterin site. ...9 KB (1,308 words) - 20:19, 22 April 2024
- ...phate)]] is converted into uric acid. AMP → IMP → Inosine → Hypoxanthine → Xanthine → Uric Acid ...ion of adenine nucleotide degradation, and is a possible weak inhibitor of xanthine dehydrogenase. As a byproduct of its fermentation process, [[beer]] additio ...14 KB (1,897 words) - 18:18, 22 April 2024
- ...phate)]] is converted into uric acid. AMP → IMP → Inosine → Hypoxanthine → Xanthine → Uric Acid ...ion of adenine nucleotide degradation, and is a possible weak inhibitor of xanthine dehydrogenase. As a byproduct of its fermentation process, [[beer]] additio ...14 KB (1,969 words) - 18:17, 22 April 2024
- 高尿酸血症の治療に用いられる[[medication/ja|医薬品]]は2つに分類される： [[xanthine oxidase inhibitor/ja|キサンチンオキシダーゼ阻害薬]]と[[uricosuric/ja|尿酸降下薬]]である。痛風の発作を繰り返す ...ebuxostat/ja|フェブキソスタット]]、[[topiroxostat/ja|トピロキソスタット]]などのキサンチンオキシダーゼ阻害薬は、[[xanthine oxidase/ja|キサンチンオキシダーゼ]]を阻害することによって尿酸の産生を減少させる。 ...17 KB (594 words) - 18:51, 22 April 2024
- ...P-4 inhibitor/ja|DPP-4阻害剤]]が最近注目を集めている。[[DPP-4 inhibitor/ja|DPP-4阻害剤]]として[[xanthine/ja|キサンチン]]（''図10''）が最初に特許に記載されたのは[[Boehringer-Ingelheim]]（BI）と[[Novo Nordis [[xanthine/ja|キサンチン]]系DPP-4阻害薬を[[sitagliptin/ja|シタグリプチン]]や[[vildagliptin/ja|ビルダグリプチン]] ...41 KB (1,558 words) - 17:16, 12 March 2024
- ===Xanthine-based compounds=== ...s have gained increased attention recently. The first patents describing [[xanthine]]s (''Figure 10'') as [[DPP-4 inhibitor]]s came from [[Boehringer-Ingelheim ...32 KB (4,417 words) - 10:31, 12 March 2024
- ===Xanthine-based compounds=== <!--T:57--> ...s have gained increased attention recently. The first patents describing [[xanthine]]s (''Figure 10'') as [[DPP-4 inhibitor]]s came from [[Boehringer-Ingelheim ...33 KB (4,561 words) - 10:30, 12 March 2024